Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

Abstract

In adults 65 years of age or older, Ad26.RSV.preF-RSV preF protein vaccine was immunogenic and prevented RSV-mediated lower respiratory tract disease. (Funded by Janssen Vaccines and Prevention; CYPRESS ClinicalTrials.gov number, NCT03982199.).